ISSN 2097-5724 CN 61-1535/R 主管·主办:陕西省疾病预防控制中心
疾 疾病预防与控制 Disease Prevention and Control 医学学术期刊 月刊
2026-06-024 临床药物与手术治疗 2026, 2(06): 93-96

针对膜诱导技术治疗下肢股骨与胫骨骨缺损的临床安全性分析

浙江省人民医院毕节医院

0下载次数 0被引频次 1阅读次数 9参考文献
知网阅读全文
摘要

目的 研究分析下肢股骨与胫骨骨缺损采用膜诱导技术治疗的临床功效及治疗安全性。方法 2022年1月至2024年12月分别就诊下肢股骨骨缺损患者20例、胫骨骨缺损患者25例,所有患者均采用膜诱导技术实施治疗,并对治疗效果进行分析。结果 两组患者术后并发症发生情况比对,并发症发生率并无显著差异(P>0.05)。患者下肢运动功能评测,术后7天除关节活动度外,两组运动、感觉、平衡、疼痛评分对比有明显差异(P<0.05),术后1月、术后3月两组下肢运动功能评测并无显著差异(P>0.05)。远期疗效组间比较,下肢股骨骨缺损、胫骨骨缺损患者远期疗效、治疗满意度均无差异(P>0.05)。结论 膜诱导技术的实施对于下肢股骨骨缺损、胫骨骨缺损均具有治疗效果,安全性及患者预后的患肢运动功能恢复情况均良好,其中以胫骨骨缺损采用该项技术治疗期间短期恢复情况略具优势性。

Abstract

Objective To study and analyze the clinical efficacy and safety of membrane induction technique in treating lower limb femoral and tibial bone defects. Methods From January 2022 to December 2024, 20 cases of femoral bone defects and 25 cases of tibial bone defects were treated. All patients were treated with membrane induction technique, and the treatment effect was analyzed. Results Comparison of postoperative complication incidence between the two groups showed no significant difference(P>0.05). Evaluation of lower limb motor function of patients, except for joint range of motion, there were significant differences in motor, sensory, balance, and pain scores between the two groups(P<0.05). There were no significant differences in lower limb motor function evaluation between the two groups at 1 month and 3 months after surgery(P>0.05). Comparison of long-term efficacy among groups showed no significant difference in the long-term efficacy of patients with lower limb femoral and tibial bone defects(P>0.05). Conclusion The implementation of membrane induction technique has therapeutic efficacy for lower limb femoral and tibial bone defects, and the safety and prognosis of the affected limb's motor function recovery are good. Among them, the short-term recovery during the treatment of tibial bone defect with this technique is slightly superior.

引用本文

按标准格式复制,或导出到文献管理软件
[1]杨治国.针对膜诱导技术治疗下肢股骨与胫骨骨缺损的临床安全性分析[J].疾病预防与控制,2026,2(06):93-96.